Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci122 in Advanced Solid Tumors
NCT06772415Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GenSci122 in solid tumor (advanced stage), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Incidence of Dose-Limiting Toxicities at 2 years and Objective Response Rate at 3 years. Started Jan 2025; status: recruiting.
02
Drugs
GenSci122
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06772415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772415.